Generic Name and Formulations:
Pyridostigmine bromide 5mg/mL; soln for IV inj; contains benzyl alcohol.
Indications for REGONOL:
As a reversal agent or antagonist to the neuromuscular blocking effects of nondepolarizing muscle relaxants.
Individualize. Give by IV inj. Usual range: 0.1–0.25mg/kg. Give atropine sulfate or equipotent dose of glycopyrrolate immediately prior to or simultaneously with Regonol.
Intestinal or urinary obstruction.
Bronchial asthma. Cardiac dysrhythmias. Electrolyte imbalance. Adrenal cortical insufficiency. Renal impairment. Neonates. Pregnancy (Cat.C).
Concomitant 4-aminopyridine may delay onset. Possible resistance to reversal with antibiotics associated with paralysis (eg, aminoglycosides, tetracyclines, bacitracin, polymyxin B, colistin, sodium colistimethate). Recurrent paralysis possible with quinidine. Magnesium salts may enhance neuromuscular blockade and interfere with restoration.
GI upset, increased salivation and bronchial secretions, miosis and diaphoresis, muscle cramps, fasciculation and weakness, rash.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Nicotinamide and Cancer
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- Opioid Prescription Protocol Decreases Opioid Use After Gynecologic Surgery
- Everolimus Plus Letrozole May Be Active in Recurrent Endometrial Carcinoma
- Affordable Care Act Increased Percentage of Insured Patients With Gynecologic Cancers
- Everolimus Plus Letrozole: An Effective First-Line Therapy for Advanced Breast Cancer
- FDA Approves Nilotinib for Pediatric Patients With CML